

Mia D SÃ¸rensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2444795/publications.pdf>

Version: 2024-02-01

34
papers

724
citations

623699

14
h-index

580810

25
g-index

34
all docs

34
docs citations

34
times ranked

1431
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour-associated CD204 ⁺ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	12
2	Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. <i>Pathology Research and Practice</i> , 2022, 231, 153798.	2.3	9
3	The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 54-60.	1.7	1
4	Albumin-corrected Zn and available free Zn-binding capacity as indicators of Zn status – potential for clinical implementation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 261-266.	1.2	3
5	Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 108-126.	3.2	10
6	The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. <i>Brain Pathology</i> , 2021, 31, e12921.	4.1	5
7	Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. <i>Stem Cell Reports</i> , 2021, 16, 281-294.	4.8	23
8	Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. <i>Pancreatology</i> , 2021, 21, 530-543.	1.1	6
9	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. <i>Scientific Reports</i> , 2021, 11, 17918.	3.3	22
10	Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 975-985.	1.7	13
11	Sodium fluorescein shows high surgeon-reported usability in glioblastoma surgery. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 344-348.	1.8	9
12	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. <i>Journal of Neuro-Oncology</i> , 2020, 147, 1-14.	2.9	18
13	Prediction of liver fibrosis severity in alcoholic liver disease by human microfibillar-associated protein 4. <i>Liver International</i> , 2020, 40, 1701-1712.	3.9	19
14	Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. <i>Histology and Histopathology</i> , 2020, 35, 811-825.	0.7	6
15	Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines. <i>Pathology and Oncology Research</i> , 2019, 25, 59-69.	1.9	3
16	High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 49-53.	2.9	40
17	Prognostic value of O ⁶ -methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 172-184.	3.2	34
18	Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 185-206.	3.2	178

#	ARTICLE	IF	CITATIONS
19	P01.114 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. <i>Neuro-Oncology</i> , 2018, 20, iii257-iii258.	1.2	0
20	P01.083 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. <i>Neuro-Oncology</i> , 2018, 20, iii249-iii249.	1.2	0
21	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. <i>Scientific Reports</i> , 2018, 8, 14965.	3.3	6
22	Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas. <i>BMC Cancer</i> , 2018, 18, 270.	2.6	29
23	SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. <i>Oncotarget</i> , 2018, 9, 9400-9414.	1.8	8
24	Expression and prognostic value of JAM-A in gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 135, 107-117.	2.9	15
25	Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. <i>PLoS ONE</i> , 2017, 12, e0172234.	2.5	60
26	APNG as a prognostic marker in patients with glioblastoma. <i>PLoS ONE</i> , 2017, 12, e0178693.	2.5	11
27	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. <i>PLoS ONE</i> , 2017, 12, e0182954.	2.5	61
28	A 4-miRNA signature to predict survival in glioblastomas. <i>PLoS ONE</i> , 2017, 12, e0188090.	2.5	21
29	Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors. <i>PLoS ONE</i> , 2016, 11, e0169129.	2.5	14
30	Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. <i>Journal of Neuro-Oncology</i> , 2016, 128, 395-404.	2.9	6
31	Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. <i>Journal of Neuro-Oncology</i> , 2016, 130, 53-62.	2.9	29
32	TMIC-18 TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHEs. <i>Neuro-Oncology</i> , 2015, 17, v218.6-v218.	1.2	0
33	Chemoresistance and Chemotherapy Targeting Stem-Like Cells in Malignant Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2015, 853, 111-138.	1.6	43
34	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. <i>CNS Oncology</i> , 2014, 3, 287-298.	3.0	10